Abstract 51P
Background
Chromosomal instability (CIN) is hallmark of cancer associated to progression and aggressiveness in prostate cancer (PCa). In the search of the mechanisms controlling CIN, long non-coding RNAs (lncRNAs) have shown to play important roles in maintaining genome stability, nevertheless, characterization of these transcripts and the networks they control in CIN regulation is still poorly understood.
Methods
RNA-seq data from the prostate cell lines PrEC (stable) and LNCaP (unstable) was analyzed to find novel lncRNAs associated with CIN. Afterwards, experimental validation of the results in PrEC and LNCaP was performed with RT-qPCR and western blot. For the functional experiments, lncRNA knockdown (KD) was performed by transfecting cells with antisense oligonucleotides (ASOs) targeting the lncRNA of interest, followed by karyotyping to assess CIN in the transfected cells. Confirmation of the lncRNA KD was performed by qPCR.
Results
After analyzing and comparing RNA-Seq data from PrEC and LNCaP, a novel lncRNA was discovered in chromosome 3. This nuclear-retained transcript is adjacent to the protein coding gene RFC4, a gene associated to CIN that participates in DNA repair and replication. RT-qPCR analysis showed that while the lncRNA is upregulated in PrEC, RFC4 is downregulated, the opposite pattern was found in LNCaP, suggesting the lncRNA as a cis-repressor of RFC4. The functional experiments confirmed that the lncRNA is a transcriptional repressor of RFC4 but also a regulator of genome stability. After KD of the lncRNA in the stable cell line PrEC, an increase in RFC4 expression was observed as well as an increased number of tetraploid cells, suggesting CIN induction after lncRNA KD. To understand how the lncRNA regulates genome stability, RNA-Seq was performed in the KD experiments showing that lncRNA KD induced disruption of different pathways needed for proper DNA replication and chromosome segregation.
Conclusions
Together our results indicate that the novel lncRNA is a regulator of CIN through regulation of RFC4 and pathways important for maintaining genome stability. The lncRNA adjacent to the protein coding gene RFC4 could be a novel biomarker for PCa progression.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Unidad de Investigación Biomédica en Cáncer - Instituto Nacional de Cancerología - Instituto de Investigaciones Biomédicas - UNAM.
Funding
Unidad de Investigación Biomédica en Cáncer - Instituto Nacional de Cancerología - Instituto de Investigaciones Biomédicas - UNAM - CONACyT.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis
Presenter: Eric Nakamura
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract